Protara Therapeutics, Inc. Payments to Acquire Debt Securities, Available-for-sale
Protara Therapeutics, Inc. (TARA) reported Payments to Acquire Debt Securities, Available-for-sale of $12.19 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2023-05-04
- Protara Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2023-03-31 was $12.19M, a 1.84% decline year-over-year.
- Protara Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2022-12-31 was $29.12M, a 231.35% increase year-over-year.
- Protara Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Protara Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2022-06-30 was $2.01M, a 24.64% increase year-over-year.
- Protara Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $43.55M, a 65.09% decline from fiscal 2021.
- Protara Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $124.75M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2023-03-31 | $12.19M 10-Q · filed 2023-05-04 | $41.31M derived: sum of 2 quarters · filed 2023-05-04 | $41.31M derived: sum of 3 quarters · filed 2023-05-04 | $43.32M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | $29.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $29.12M derived: sum of 2 quarters · filed 2023-03-08 | $31.14M derived: sum of 3 quarters · filed 2023-03-08 | $43.55M 10-K · filed 2023-03-08 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.01M derived: sum of 2 quarters · filed 2022-11-03 | $14.43M 10-Q · filed 2022-11-03 | $23.22M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $14.43M 10-Q · filed 2022-08-09 | $23.22M derived: sum of 3 quarters · filed 2023-05-04 | $39.60M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $12.41M 10-Q · filed 2023-05-04 | $21.20M derived: sum of 2 quarters · filed 2023-05-04 | $37.59M derived: sum of 3 quarters · filed 2023-05-04 | $39.20M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $8.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $25.17M derived: sum of 2 quarters · filed 2023-03-08 | $26.79M derived: sum of 3 quarters · filed 2023-03-08 | $124.75M 10-K · filed 2023-03-08 |
| 2021-09-30 | $16.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $18.00M derived: sum of 2 quarters · filed 2022-11-03 | $115.96M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $99.57M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $97.96M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |